Altre lingue Apogee Therapeutics, Inc.

Azioni

APGE

US03770N1019

Tempo differito Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
37,5 ^USD	-1,86%		-1,96%	+34,22%

28/05	Apogee Therapeutics, Inc. nomina Lisa Bollinger nel suo Consiglio di Amministrazione	CI
15/05	Apogee annuncia il dosaggio del primo paziente nello studio di Fase 2 sulla dermatite atopica di APG777, un nuovo anticorpo anti-Il-13 ad emivita estesa per via sottocutanea per il trattamento della dermatite atopica e di altre malattie infiammatorie.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000E Value Index	01/07
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD	28/05
Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors	28/05
Apogee Therapeutics to Participate in Upcoming June Investor Conferences	23/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Therapeutics' Q1 Net Loss Widens	13/05
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13/05
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06/05
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25/03
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25/03
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	18/03
Apogee Closes $483 million Upsized Stock Offering	12/03
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12/03
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08/03
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08/03
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06/03
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06/03
Apogee Therapeutics Unveils $350 Million Share Offering	05/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Apogee Therapeutics, Inc.

Azioni

APGE

US03770N1019

Altre lingue

Filtri